Proteínas Quinasas y Oncología Molecular

Publicaciones

  • Biochimica et Biophysica Acta

    01/11/2019

    European journal of medical genetics

    Identification of a somatic mutation in the RHEB gene through high depth and ultra-high depth next generation sequencing in a patient with Hemimegalencephaly and drug resistant Epilepsy

    Salinas V, Vega P, Piccirilli MV, Chicco C, Ciraolo C, Christiansen S, Consalvo D, Maturo JP, Medina N, González-Morón D, Novaro V, Perrone C, García MDC, Agosta G, Silva W, Kauffman M.

  • International Journal of Cancer

    01/10/2019

    International Journal of Cancer

    FGF2 Induces Breast Cancer Growth through Ligand-Independent Activation and Recruitment of ERα and PRBΔ4 Isoform to MYC Regulatory Sequences

    Giulianelli S, Riggio M, Guillardoy T, Pérez Piñero C, Gorostiaga MA, Sequeira G, Pataccini G, Abascal MF, Toledo MF, Jacobsen BM, Guerreiro AC, Barros A, Novaro V, Monteiro FL, Amado F, Gass H, Abba M, Helguero LA, Lanari C.

  • 18/09/2019

    Cell Death and Disease

    Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein

    Byun JS, Park S, Yi DI, Shin JH, Hernandez SG, Hewitt SM, Nicklaus MC, Peach ML, Guasch L, Tang B, Wakefield LM, Yan T, Caban A, Jones A, Kabbout M, Vohra N, Nápoles AM, Singhal S, Yancey R, De Siervi A, Gardner K.

  • 01/04/2019

    Cell Death and Disease

    CTBP1 depletion on prostate tumors deregulates miRNA/mRNA expression and impairs cancer progression in metabolic syndrome mice

    Dalton GN, Massillo C, Scalise GD, Duca R, Porretti J, Farré PL, Gardner K, Paez A, Gueron G, De Luca P, De Siervi A.

  • International Journal of Cancer

    01/03/2019

    International Journal of Cancer

    CTBP1/CYP19A1/Estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome

    Massillo C, Dalton GN, Porretti J, Scalise GD, Farré PL, Piccioni F, Secchiari F, Pascuali N, Clyne C, Gardner K, De Luca P, De Siervi A.

  • Current Drug Targets

    01/01/2019

    Current pharmaceutical biotechnology

    Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer

    Zalazar F, Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, Siervi A.

  • International Journal of Cancer

    15/08/2018

    International Journal of Cancer

    CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease

    Porretti J, Dalton GN, Massillo C, Scalise GD, Farré PL, Elble R, Gerez EN, Accialini P, Cabanillas AM, Gardner K, De Luca P, De Siervi A.

  • Aging (Albany NY)

    13/02/2018

    Oncotarget

    CTBP1 and metabolic syndrome induce an mRNA and miRNA expression profile critical for breast cancer progression and metastasis

    Farré PL, Scalise GD, Duca RB, Dalton GN, Massillo C, Porretti J, Graña K, Gardner K, De Luca P, De Siervi A.

  • Reproduction

    01/10/2017

    Reproduction

    Implications of microRNA dysregulation in the development of prostate cancer

    Massillo C, Dalton GN, Farré PL, De Luca P, De Siervi A.

  • 13/03/2017

    Scientific Reports

    AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins

    Riggio M, Perrone MC, Polo ML, Rodriguez MJ, May M, Abba M, Lanari C, Novaro V.